Travere reports record Q4 FILSPARI sales of $103M; FSGS PDUFA decision due Jan 13

Travere Therapeutics, Inc.

Preliminary Q4 2025 total U.S. net product sales ~$127M; FILSPARI sales ~$103M (+108% YoY).
FY2025 total U.S. net product sales ~$410M; FILSPARI full-year sales ~$322M.
Cash, equivalents and marketable securities ~$323M at year-end 2025.
FSGS sNDA PDUFA target date Jan 13, 2026; responses to FDA's info requests submitted and under review.
Pegtibatinase Phase 3 HARMONY study to restart in Q1 2026 after manufacturing optimization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.